Predictive factors in prostate cancer: implications for decision making (Q35193301)

7 August 2017

1 reference

title

Predictive factors in prostate cancer: implications for decision making (English)

1 reference

7 August 2017

1 reference

2

Edouard J Trabulsi

1 reference

7 August 2017

Ofer Yossepowitch

1

1 reference

PubMed ID

12901292

7 August 2017

Michael W Kattan

series ordinal

3

1 reference

PubMed ID

12901292

7 August 2017

Peter T Scardino

series ordinal

4

1 reference

7 August 2017

1 June 2003

1 reference

7 August 2017

1 reference

7 August 2017

21

1 reference

7 August 2017

3

1 reference

7 August 2017

465-480

1 reference

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

7 August 2017

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Inter-observer variation in assessment of the prostate by digital rectal examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Interexaminer variability of digital rectal examination in detecting prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Ability of sextant biopsies to predict radical prostatectomy stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Evaluating prostate needle biopsy: therapeutic and prognostic importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Current trends in prostate cancer diagnosis and staging among United States urologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Current role of MR imaging in the staging of adenocarcinoma of the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Regulation and function of the p53 tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Monoclonal antibody Ki-67: its use in histopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Role of transforming growth factor-beta1 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Consensus review of the clinical utility of DNA content cytometry in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Trisomy 7: a potential cytogenetic marker of human prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Reference ranges for serum prostate-specific antigen in black and white men without cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prostate-specific antigen density

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Age-specific reference ranges for serum prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Select transition zone prostate cancers may be radiocurable despite markedly elevated prostate-specific antigen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Cancer statistics for African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prediction of capsular perforation and seminal vesicle invasion in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Transrectal ultrasound in management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prostatic carcinoma: staging with MR imaging at 1.5 T

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prostate imaging may not be necessary in nonpalpable carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Tumor angiogenesis and tissue factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Assessment of the vascularization in prostatic carcinoma: a morphometric investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

For proteomics research, a new race has begun

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120018239

21 January 2018

Identifiers

DOI

10.1081/CNV-120018239

1 reference

7 August 2017

1 reference

PubMed ID

12901292